{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:36:24Z","timestamp":1781624184392,"version":"3.54.5"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","funder":[{"name":"Armed Forces Health Surveillance Center\u2013Global Emerging Infectious Surveillance Partners","award":["20160590205"],"award-info":[{"award-number":["20160590205"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Vancomycin-resistant enterococci (VRE) are classified by the Centers for Diseases Control and Prevention as a serious antibiotic resistance threat. Our study aims to characterize the epidemiology, associated conditions, and outcomes of VRE infections among hospitalized patients in the U.S. military health system (MHS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We performed a retrospective cohort study of patients with VRE infection using the MHS database. Cases included all patients admitted to a military treatment facility for \u22652 days from October 2008 to September 2015 with a clinical culture growing Enterococcus faecalis, Enterococcus faecium, or Enterococcus species (unspecified), reported as resistant to vancomycin. Co-morbid conditions and procedures associated with VRE infection were identified by multivariable conditional logistic regression. Patient case-mix adjusted outcomes including in-hospital mortality, length of stay, and hospitalization cost were evaluated by high-dimensional propensity score adjustment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During the seven-year study period and among 1,161,335 hospitalized patients within the MHS, we identified 577 (0.05%) patients with VRE infection. A majority of VRE infections were urinary tract infections (57.7%), followed by bloodstream (24.7%), other site\/device-related (12.9%), respiratory (2.9%), and wound infections (1.8%). Risk factors for VRE infection included invasive gastrointestinal, pulmonary, and urologic procedures, indwelling devices, and exposure to 4th generation cephalosporins, but not to glycopeptides. Patients hospitalized with VRE infection had significantly higher hospitalization costs (attributable difference [AD] $135,534, P&amp;lt;0.001), prolonged hospital stays (AD 20.44 days, P&amp;lt;0.001, and higher in-hospital mortality (case-mix adjusted odds ratio 5.77; 95% confidence interval 4.59-7.25).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>VRE infections carry a considerable burden for hospitalized patients given their impact on length of stay, hospitalization costs, and in-hospital mortality. Active surveillance and infection control efforts should target those identified as high-risk for VRE infection. Antimicrobial stewardship programs should focus on limiting exposure to 4th generation cephalosporins.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/milmed\/usaa229","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T01:48:12Z","timestamp":1611625692000},"page":"100-107","source":"Crossref","is-referenced-by-count":9,"title":["Epidemiology and Outcomes of Vancomycin-Resistant Enterococcus Infections in the U.S. Military Health System"],"prefix":"10.1093","volume":"186","author":[{"given":"David R","family":"Stagliano","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Uniformed Services University, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apryl","family":"Susi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Uniformed Services University, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Maj","given":"Daniel J","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Uniformed Services University, Bethesda, MD 20814, USA"},{"name":"Department of Pediatrics, Uniformed Services University, Naval Medical Center Portsmouth, Portsmouth, VA 23708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Lt Col","given":"Cade M","family":"Nylund","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Uniformed Services University, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"2021012913540619600_R1","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/ajt.13893","article-title":"Vital signs: preventing antibiotic-resistant infections in hospitals\u2014United States, 2014","volume":"16(7)","author":"Weiner","year":"2016","journal-title":"Am J Transplant"},{"key":"2021012913540619600_R2","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic Resistance Threats in the United States, 2019","author":"Center for Disease Control and Prevention","year":"2019"},{"key":"2021012913540619600_R3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.diagmicrobio.2013.11.011","article-title":"Prevalence of antibiotic resistance in US hospitals","volume":"78(3)","author":"Edelsberg","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021012913540619600_R4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jhin.2013.06.016","article-title":"Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay","volume":"85(1)","author":"Lloyd-Smith","year":"2013","journal-title":"J Hosp Infect"},{"key":"2021012913540619600_R5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1017\/ice.2016.254","article-title":"Incidence and outcomes associated with infections caused by vancomycin-resistant enterococci in the United States: systematic literature review and meta-analysis","volume":"38(2)","author":"Chiang","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021012913540619600_R6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1017\/ice.2015.228","article-title":"VRE and VSE bacteremia outcomes in the era of effective VRE therapy: a systematic review and meta-analysis","volume":"37(1)","author":"Prematunge","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021012913540619600_R7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijid.2014.02.012","article-title":"Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study","volume":"26","author":"Billington","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2021012913540619600_R8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ajic.2019.10.006","article-title":"Clinical characteristics, risk factors, and outcomes of patients hospitalized in the US military health system with carbapenem-resistant Enterobacteriaceae infection","volume":"48(6)","author":"Adams","year":"2020","journal-title":"Am J Infect Control"},{"key":"2021012913540619600_R9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.idc.2016.07.009","article-title":"Vancomycin-resistant enterococci: epidemiology, infection prevention, and control","volume":"30(4)","author":"Reyes","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"2021012913540619600_R10","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/781679","article-title":"Glycopeptide resistance in gram-positive cocci: a review","volume":"2012","author":"Sujatha","year":"2012","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"2021012913540619600_R11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro2761","article-title":"The rise of the Enterococcus: beyond vancomycin resistance","volume":"10(4)","author":"Arias","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"2021012913540619600_R12","volume-title":"Clinical Classifications Software (CCS) for ICD-9-CM","author":"Healthcare Cost and Utilization Project"},{"key":"2021012913540619600_R13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(88)91037-9","article-title":"Vancomycin-resistant enterococci","volume":"1(8575-6)","author":"Uttley","year":"1988","journal-title":"Lancet"},{"key":"2021012913540619600_R14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJM198807213190307","article-title":"Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium","volume":"319(3)","author":"Leclercq","year":"1988","journal-title":"N Engl J Med"},{"key":"2021012913540619600_R15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1086\/671724","article-title":"Incidence trends in pathogen-specific central line-associated bloodstream infec-tions in US intensive care units, 1990-2010","volume":"34(9)","author":"Fagan","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021012913540619600_R16","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/jac\/dkw319","article-title":"Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency","volume":"71(12)","author":"Mendes","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021012913540619600_R17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015-2017","volume":"41(1)","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021012913540619600_R18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010","volume":"34(1)","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021012913540619600_R19","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1017\/S095026881300318X","article-title":"Antimicrobial resistance in eight US hospitals along the US-Mexico border, 2000-2006","volume":"142(11)","author":"Benoit","year":"2014","journal-title":"Epidemiol Infect"},{"key":"2021012913540619600_R20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cger.2007.03.009","article-title":"Principles of antimicrobial use in older adults","volume":"23(3)","author":"Herring","year":"2007","journal-title":"Clin Geriatr Med"},{"key":"2021012913540619600_R21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.diagmicrobio.2006.06.004","article-title":"Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology\/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America)","volume":"56(1)","author":"Kirby","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021012913540619600_R22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1469-0691.2011.03591.x","article-title":"Differing risk factors for vancomycin-resistant and vancomycin-sensitive enterococcal bacteraemia","volume":"18(4)","author":"Peel","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2021012913540619600_R23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajic.2013.11.010","article-title":"Identification of temporal clusters and risk factors of bacteremia by nosocomial vancomycin-resistant enterococci","volume":"42(4)","author":"da Silva","year":"2014","journal-title":"Am J Infect Control"},{"key":"2021012913540619600_R24","first-page":"DC06","article-title":"Screening for intestinal colonization with vancomycin resistant enterococci and associated risk factors among patients admitted to an adult intensive care unit of a large teaching hospital","volume":"10(9)","author":"Amberpet","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"2021012913540619600_R25","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/j.ijid.2012.09.019","article-title":"Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital","volume":"17(4)","author":"Sohn","year":"2013","journal-title":"Int J Infect Dis"},{"key":"2021012913540619600_R26","first-page":"165","article-title":"Changes in bacterial flora and antibiotic resistance in clinical samples isolated from patients hospitalized in the Military Institute of Medicine in Warsaw, Poland, between 2005-2012","volume":"71(2)","author":"Guzek","year":"2017","journal-title":"Przegl Epidemiol"},{"key":"2021012913540619600_R27","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJM200012283432604","article-title":"Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients","volume":"343(26)","author":"Donskey","year":"2000","journal-title":"N Engl J Med"},{"key":"2021012913540619600_R28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1086\/649020","article-title":"Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort","volume":"31(1)","author":"Butler","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021012913540619600_R29","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/cid\/cis550","article-title":"Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation","volume":"55(6)","author":"Vydra","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2021012913540619600_R30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciu319","article-title":"The antimicrobial resistance monitoring and research (ARMoR) program: the US Department of Defense response to escalating antimicrobial resistance","volume":"59(3)","author":"Lesho","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/Supplement_1\/100\/36145082\/usaa229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/Supplement_1\/100\/36145082\/usaa229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T13:54:39Z","timestamp":1611928479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/186\/Supplement_1\/100\/6119441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":30,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2021,1,25]]},"published-print":{"date-parts":[[2021,1,25]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usaa229","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2021,1,1]]}}}